| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
|
Eapen, Mary
|
|
2017
|
4 |
7 |
p. e325-e333
nvt p.
|
artikel
|
| 2 |
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
|
Clark, Richard E
|
|
2017
|
4 |
7 |
p. e310-e316
nvt p.
|
artikel
|
| 3 |
Do big numbers assure high-quality of data?
|
Crocetti, Emanuele
|
|
2017
|
4 |
7 |
p. e309-
1 p.
|
artikel
|
| 4 |
How to define treatment failure for JAK inhibitors
|
Kvasnicka, Hans Michael
|
|
2017
|
4 |
7 |
p. e305-e306
nvt p.
|
artikel
|
| 5 |
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
|
Harrison, Claire N
|
|
2017
|
4 |
7 |
p. e317-e324
nvt p.
|
artikel
|
| 6 |
Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study
|
Rawstron, Andy C
|
|
2017
|
4 |
7 |
p. e334-e340
nvt p.
|
artikel
|
| 7 |
The DESTINY of chronic myeloid leukeamia
|
Abruzzese, Elisabetta
|
|
2017
|
4 |
7 |
p. e303-e304
nvt p.
|
artikel
|
| 8 |
The need for better legislation for generic drug manufacturers
|
The Lancet Haematology,
|
|
2017
|
4 |
7 |
p. e302-
1 p.
|
artikel
|
| 9 |
Unrelated cord blood transplantation for non-malignant diseases: every HLA allele counts
|
Scaradavou, Andromachi
|
|
2017
|
4 |
7 |
p. e307-e308
nvt p.
|
artikel
|
Tijdschrift beschrijving